Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables: 2020-2023

Historic Receivables for Relay Therapeutics (RLAY) over the last 3 years, with Sep 2023 value amounting to $211,000.

  • Relay Therapeutics' Receivables fell 95.90% to $211,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $10.7 million, marking a year-over-year decrease of 46.67%. This contributed to the annual value of $5.2 million for FY2022, which is 5.65% up from last year.
  • As of Q3 2023, Relay Therapeutics' Receivables stood at $211,000, which was up 170.51% from $78,000 recorded in Q2 2023.
  • Relay Therapeutics' 5-year Receivables high stood at $82.7 million for Q4 2020, and its period low was $78,000 during Q2 2023.
  • Moreover, its 3-year median value for Receivables was $5.0 million (2021), whereas its average is $4.0 million.
  • In the last 5 years, Relay Therapeutics' Receivables increased by 13.77% in 2022 and then slumped by 98.47% in 2023.
  • Quarterly analysis of 4 years shows Relay Therapeutics' Receivables stood at $82.7 million in 2020, then tumbled by 94.02% to $4.9 million in 2021, then increased by 5.65% to $5.2 million in 2022, then tumbled by 95.90% to $211,000 in 2023.
  • Its Receivables was $211,000 in Q3 2023, compared to $78,000 in Q2 2023 and $5.2 million in Q1 2023.